EGFR inhibitors show higher response rates but no survival advantage over bevacizumab in CRLMComparing two types of drugs for colorectal cancer liver metastases

Critical reviews in oncology/hematology Published November 2, 2026 Study authors: Corallo Salvatore, Cicerone Ottavia, Brigati Cecilia, Pagani Anna, Colletto Luigi, Pellizzari Benede… PubMed ↗ DOI ↗ Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Note that EGFR inhibitors improve response rates and depth of response but do not improve survival over bevacizumab.

This meta-analysis evaluated the efficacy of chemotherapy combined with either an EGFR inhibitor or bevacizumab in 795 patients with initially unresectable RAS wild-type colorectal liver metastases (CRLM). The analysis focused on primary outcomes of progression-free survival (PFS) and secondary outcomes including overall survival (OS), response rate (RR), R0 resection rate, and depth of response (DpR).

The meta-analysis found that while EGFRi-based regimens resulted in statistically significant improvements in response rate (OR 1.98) and depth of response (OR 1.70), these improvements did not translate into significant clinical gains in survival. Specifically, no statistically significant differences were observed in progression-free survival or overall survival when comparing EGFR inhibitors to bevacizumab. Additionally, no significant difference was found in the R0 resection rate between the two treatment groups.

Clinical implications are limited by the lack of a survival advantage for either anti-EGFRs or bevacizumab in this specific population. While EGFR inhibitors may enhance the depth of response and response rate, these metrics did not correlate with improved survival outcomes in this study. The findings suggest that while treatment choice may impact tumor response characteristics, it may not currently alter survival outcomes for patients with unresectable RAS wild-type CRLM.

How this fits prior evidence

This meta-analysis addresses a gap in treatment selection for patients with unresectable RAS wild-type colorectal liver metastases. While previous evidence has identified prognostic biomarkers such as ANXA1 dominance (HR 1.43) and Periostin, and identified surgical interventions like prophylactic HIPEC to improve metastasis-free survival, this study specifically compares the efficacy of EGFR inhibitors against bevacizumab. It confirms that while EGFR inhibitors may improve response rates (OR 1.98) and depth of response (OR 1.70), they do not provide a survival advantage over bevacizumab in this population.

When colorectal cancer spreads to the liver and cannot be removed by surgery right away, doctors must choose the best treatment path. This study looked at 795 patients to compare two common options: chemotherapy combined with an EGFR inhibitor versus chemotherapy combined with bevacizumab. Both are used to manage the disease and improve outcomes.

While the results showed that patients on the EGFR inhibitor had better response rates and a deeper response to the treatment, the findings were more mixed regarding survival. Specifically, the study found no significant difference in progression-free survival or overall survival between the two groups. This means that while one drug might shrink tumors more effectively, it did not result in a longer life for patients in this specific group.

Because the study found no clear winner for survival, choosing between these treatments remains complex. Doctors must weigh the different ways these drugs work to find the best fit for each individual patient's needs.

What this means for you:

EGFR inhibitors showed better tumor response rates, but neither drug showed a survival advantage over the other.

Common questions

Does one treatment help patients live longer?

The study of 795 patients found no statistically significant differences in overall survival or progression-free survival between the two treatment groups. This means that while the drugs work differently in how they affect the tumor, neither was shown to provide a clear advantage in extending life for patients with this specific type of cancer.

What are the differences in how the tumors respond to treatment?

Patients receiving the chemotherapy and EGFR inhibitor combination showed statistically significant improvements in response rates and depth of response compared to those on bevacizumab. This means the tumors responded more strongly to the EGFR inhibitor, even though the overall survival rates were similar between both groups.

Is one treatment better for surgery?

The study looked at the R0 resection rate, which measures the success of removing the tumor. However, the results showed no statistically significant difference between the two treatment groups regarding the rate of successful surgery.

Study Details

Study typeMeta analysis

Sample sizen = 795

EvidenceLevel 1

PublishedNov 2026

PMID42562243

View Original Abstract ↓

The selection of optimal conversion therapy for patients with initially unresectable colorectal liver metastases (CRLM) remains a significant clinical challenge. In patients with RAS wild-type disease, a key therapeutic decision involves whether to combine chemotherapy with an EGFR inhibitor (EGFRi) or bevacizumab. A systematic literature review and meta-analysis of randomised controlled trials (RCTs) published between 2015 and 2025 were conducted to compare chemotherapy plus either an EGFRi or bevacizumab as first-line treatment for patients with RAS wild-type metastatic colorectal cancer and liver-limited disease. Analyses encompassed both the overall population and subgroups defined by primary tumor location (PTL). Six RCTs, including data from 795 patients with CRLM, were identified. No statistically significant differences were found between EGFRi- and bevacizumab-based regimens for progression-free survival (PFS) and overall survival (OS). Four studies contributed to analyses of response rate (RR) and complete (R0) resection rate, while three studies contributed to the depth of response (DpR) analysis. EGFRi-based regimens demonstrated statistically significant improvements in both RR and DpR, with pooled odds ratios (ORs) of 1.98 and 1.70, respectively. No statistically significant difference in R0 resection rates was observed. Subgroup analyses by PTL revealed no statistically significant survival advantage for either agent in either left- or right-sided subgroups. This comprehensive meta-analysis identified no significant survival advantage for either anti-EGFRs or bevacizumab in patients with initially unresectable RAS wild-type CRLM. Further research is warranted to elucidate why the increased and deeper responses observed with anti-EGFRs do not result in higher R0 resection rates or improved survival.

EGFR inhibitors show higher response rates but no survival advantage over bevacizumab in CRLMComparing two types of drugs for colorectal cancer liver metastases

How this fits prior evidence

Common questions

Study Details

Higher TyG Index Linked to 4.36-Fold Increased Odds of NAFLD in Large Meta-Analysis

TyG Index Linked to Higher Fatty Liver Risk

Clinical research that matters. Delivered to your inbox.

EGFR inhibitors show higher response rates but no survival advantage over bevacizumab in CRLMComparing two types of drugs for colorectal cancer liver metastases

How this fits prior evidence

Common questions

More on Colorectal Cancer

Study Details

Higher TyG Index Linked to 4.36-Fold Increased Odds of NAFLD in Large Meta-Analysis

TyG Index Linked to Higher Fatty Liver Risk

Clinical research that matters. Delivered to your inbox.

Related in Gastroenterology

From Other Specialties